Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipotecan in poorly differentiated neuroendocrine carcinomas
NCT02457273Phase 2Completed
- Sponsor
- National Health Research Institutes
- Start
- Jul 2015
- Primary completion
- Apr 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lipotecan in neuroendocrine carcinoma (NEC), sponsored by National Health Research Institutes. Started Jul 2015; status: completed.
02
Drugs
lipotecan
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT02457273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02457273.